BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-
camptothecin, is a novel semi-synthetic, highly lipophilic,
silicon-containing
camptothecin and an inhibitor of
topoisomerase I. It has been supercomputer engineered for superior oral bioavailability, superior
lactone stability, broad anti-
tumor activity, increased potency and insensitivity to Pgp/MRP/LRP drug resistance. We determined the efficacy of
BNP1350 in experimental human
colon cancer and compared its anti-
tumor effects with those of
CPT-11/
SN-38. We also determined a possible influence of Pgp, MRP and LRP on the efficacy of
BNP1350. The in vitro anti-proliferative capacity of the compounds using various exposure times was assessed in five
colon cancer cell lines and indicated that
BNP1350 was similarly effective or slightly more potent than
SN-38. Four cell lines of other origin with sublines expressing Pgp, MRP and/or LRP showed that
BNP1350 was significantly more effective than
SN-38 (p < 0.05) and that the activity of
BNP1350 was not reduced in multidrug-resistant cells. For in vivo experiments,
BNP1350 was given 1.0 mg/kg i.p. or 1.5 mg/kg p.o. daily x 5 and
CPT-11 20 mg/kg i.p. daily x 5 being equitoxic schedules in nude mice bearing s.c. human
tumor xenografts. The schedules were studied in
colon cancer xenografts COLO320, COLO205 or WiDr as well as in two Pgp-positive xenografts 2780AD and BRO/mdr1.1 and the parental Pgp-negative A2780
ovarian cancer xenografts and BRO
melanoma xenografts. Growth inhibition of >50% was obtained for
BNP1350 given i.p. in six out of the seven xenografts studied.
BNP1350 was similarly effective when given i.p. or p.o.
CPT-11 was as effective as
BNP1350, except in BRO and BRO/mdr1.1 xenografts. Pgp expression in xenografts in vivo confirmed that there was no negative influence on the efficacy of
BNP1350. In conclusion,
BNP1350 shows a broad spectrum of activity in experimental human
tumors and is a suitable candidate for oral treatment of
cancer.